Department of Laboratory Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Anticancer Res. 2010 Jul;30(7):2897-904.
We investigated the immunohistochemical expression of estrogen receptors alpha (ERalpha) and beta (ERbeta) in pituitary adenoma subtypes combined with clinicopathological factors.
Pituitary adenomas (n=75) were immunostained for ERalpha and ERbeta using the streptavidin-biotin-peroxidase complex method with a monoclonal ERalpha antibody and polyclonal ERbeta antibody.
Nuclear immunoreactivity for both receptors was highest among PRL, FSH/LH, null cell, and GH adenomas. ACTH, silent subtypes I and II corticotrophs, and subtype III adenomas were the least immunoreactive for both receptors. ACTH adenomas expressed significantly less ERalpha than FSH-LH, GH, and null cell adenomas. A significantly elevated ERalpha expression was observed in macroadenomas compared to microadenomas and non-invasive compared to invasive tumors.
ERalpha and ERbeta are differentially expressed in the various pituitary adenoma subtypes suggesting a cell-specific function for these receptors. To elucidate the role of ERalpha in tumor size and invasiveness, additional studies are required.
我们研究了结合临床病理因素的垂体腺瘤亚型中雌激素受体 α（ERα）和 β（ERβ）的免疫组织化学表达。
使用链霉亲和素-生物素-过氧化物酶复合物方法，用单克隆 ERα 抗体和多克隆 ERβ 抗体对 75 例垂体腺瘤进行 ERα 和 ERβ 的免疫染色。
两种受体的核免疫反应性在 PRL、FSH/LH、无细胞和 GH 腺瘤中最高。ACTH、沉默亚型 I 和 II 促皮质素细胞和 III 型腺瘤对两种受体的免疫反应性最低。ACTH 腺瘤表达的 ERα 明显少于 FSH/LH、GH 和无细胞腺瘤。与微腺瘤和非侵袭性肿瘤相比，大腺瘤中 ERα 的表达显著升高。
ERα 和 ERβ 在各种垂体腺瘤亚型中表达不同，提示这些受体具有细胞特异性功能。为了阐明 ERα 在肿瘤大小和侵袭性中的作用，需要进一步的研究。
Zotero 插件